​
​

Pharvaris (PHVS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PHVS Stock Forecast

Pharvaris stock forecast is as follows: an average price target of $39.67 (represents a 77.97% upside from PHVS’s last price of $22.29) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

PHVS Price Target

The average price target for Pharvaris (PHVS) is $39.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $27.00. This represents a potential 77.97% upside from PHVS's last price of $22.29.

PHVS Analyst Ratings

Buy

According to 4 Wall Street analysts, Pharvaris's rating consensus is 'Buy'. The analyst rating breakdown for PHVS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Pharvaris Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2024Justin KimOppenheimer--112.87%88.43%
Apr 11, 2024Jonathan WollebenJMP Securities--124.52%124.32%
Sep 25, 2023Laura ChicoWedbush--30.62%21.13%
Jan 11, 2023JMP Securities--122.87%3.19%
Dec 09, 2022JMP Securities--91.97%-1.30%
Row per page
Go to

The latest Pharvaris stock forecast, released on Oct 14, 2024 by Justin Kim from Oppenheimer, set a price target of $42.00, which represents a 112.87% increase from the stock price at the time of the forecast ($19.73), and a 88.43% increase from PHVS last price ($22.29).

Pharvaris Price Target by Period

1M3M12M
# Anlaysts-12
Avg Price Target-$42.00$46.00
Last Closing Price$22.29$22.29$22.29
Upside/Downside-100.00%88.43%106.37%

In the current month, the average price target of Pharvaris stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pharvaris's last price of $22.29. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024OppenheimerOutperformOutperformHold
Sep 06, 2024OppenheimerOutperformOutperformHold
Jul 03, 2024OppenheimerOutperformOutperformHold
Aug 15, 2023Morgan StanleyOverweightUpgrade
Feb 03, 2023SVB LeerinkOutperformOutperformHold
Jan 11, 2023JMP SecuritiesMarket OutperformMarket OutperformHold
Dec 09, 2022JMP SecuritiesMarket OutperformMarket OutperformHold
Row per page
Go to

Pharvaris's last stock rating was published by Oppenheimer on Oct 14, 2024. The company gave PHVS a "Outperform" rating, the same as its previous rate.

Pharvaris Financial Forecast

Pharvaris Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast$7.60M$2.38M---------
High Forecast$7.60M$2.38M---------
Low Forecast$7.60M$2.38M---------
# Analysts11---------
Surprise %-----------

Pharvaris's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PHVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Pharvaris EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11---------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict PHVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Pharvaris's previous annual EBITDA (undefined) of $NaN.

Pharvaris Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11---------
Net Income-----------
Avg Forecast$-50.74M$-52.79M$-50.23M$-37.93M$-42.56M$-41.48M$-41.11M$-40.37M$-40.60M$-35.56M$-31.88M
High Forecast$-50.74M$-52.79M$-50.23M$-37.93M$-42.56M$-41.48M$-41.11M$-39.80M$-33.75M$-35.56M$-31.88M
Low Forecast$-50.74M$-52.79M$-50.23M$-37.93M$-42.56M$-41.48M$-41.11M$-40.94M$-53.25M$-35.56M$-31.88M
Surprise %-----------

Pharvaris's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PHVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Pharvaris SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11---------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Pharvaris's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PHVS last annual SG&A of $NaN (undefined).

Pharvaris EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts11---------
EPS-----------
Avg Forecast$-0.94$-0.98$-0.93$-0.70$-0.79$-0.77$-0.76$-0.75$-0.75$-0.66$-0.59
High Forecast$-0.94$-0.98$-0.93$-0.70$-0.79$-0.77$-0.76$-0.74$-0.63$-0.66$-0.59
Low Forecast$-0.94$-0.98$-0.93$-0.70$-0.79$-0.77$-0.76$-0.76$-0.99$-0.66$-0.59
Surprise %-----------

According to undefined Wall Street analysts, Pharvaris's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PHVS previous annual EPS of $NaN (undefined).

Pharvaris Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PMVPPMV Pharmaceuticals--1018.01%Buy
PEPGPepGen--568.93%Buy
ANTXAN2 Therapeutics--552.99%Buy
HOWLWerewolf Therapeutics--531.58%Buy
MOLNMolecular Partners--448.20%Buy
ANEBAnebulo Pharmaceuticals--310.96%Buy
RZLTRezolute--174.95%Buy
STOKStoke Therapeutics--167.72%Buy
ELYMEliem Therapeutics--154.40%Buy
MLYSMineralys Therapeutics--140.19%Buy
TYRATyra Biosciences--100.57%Buy
PHVSPharvaris--77.97%Buy
DSGNDesign Therapeutics--72.06%Buy
JANXJanux Therapeutics--21.65%Buy
IKNAIkena Oncology---22.22%Buy

PHVS Forecast FAQ

Is Pharvaris a good buy?

Yes, according to 4 Wall Street analysts, Pharvaris (PHVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PHVS's total ratings.

What is PHVS's price target?

Pharvaris (PHVS) average price target is $39.67 with a range of $27 to $50, implying a 77.97% from its last price of $22.29. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Pharvaris stock go up soon?

According to Wall Street analysts' prediction for PHVS stock, the company can go up by 77.97% (from the last price of $22.29 to the average price target of $39.67), up by 124.32% based on the highest stock price target, and up by 21.13% based on the lowest stock price target.

Can Pharvaris stock reach $30?

PHVS's average twelve months analyst stock price target of $39.67 supports the claim that Pharvaris can reach $30 in the near future.

What are Pharvaris's analysts' financial forecasts?

Pharvaris's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-166M (high $-165M, low $-166M), average SG&A $0 (high $0, low $0), and average EPS is $-3.068 (high $-3.058, low $-3.079). PHVS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.98M (high $9.98M, low $9.98M), average EBITDA is $0 (high $0, low $0), average net income is $-192M (high $-192M, low $-192M), average SG&A $0 (high $0, low $0), and average EPS is $-3.554 (high $-3.554, low $-3.554).